AI Stock Monitor
JNJ - Johnson & Johnson
Johnson & Johnson is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Pharmaceuticals · Medical Devices · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NYSE · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
70
/100
Price History
JNJ chart
AI-Assisted Chart Analysis
Johnson & Johnson technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Mixed trend: the latest level is above its 20-period average, without full long-term confirmation.
RSI is 40, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 265.58. A break below 247.02 invalidates the near-term support setup.
The first resistance/watch zone is 278.43. A confirmed break above 278.43 supports continuation.
Annualized realized volatility is +23.5%. Maximum lookback drawdown is -7.6%, from a high-water mark of 267.24 to 247.02.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported JNJ at 270.68 USD; the latest daily move rose +0.56%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified +0.56% daily move is current market context for Johnson & Johnson.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The outlook is bullish, driven by a combination of successful R&D execution and potential strategic portfolio pruning.
- Evidence: The potential sale of the orthopedics business is a significant catalyst that could re-rate the stock by focusing investor attention on higher-growth segments.
- Uncertainty: While the Contineum depression drug failure is a disappointment, it is overshadowed by the positive momentum in the multiple myeloma and psoriasis franchises.
- Watch: Investors should monitor the progress of the DePuy divestiture and the commercial rollout of newly approved therapies to confirm the company's ability to maintain its growth premium.
Key Risks
- The potential divestiture of the orthopedics business may face execution risks or valuation discrepancies that could disappoint investors if the final terms are unfavorable.
- Ongoing litigation and the looming patent cliff for key legacy drugs remain significant overhangs that could pressure margins and long-term cash flow stability.
- Failure to successfully integrate or commercialize new pipeline assets, such as the recently approved ICOTYDE, would weaken the growth thesis and increase reliance on aging blockbuster drugs.
Upcoming Catalysts
- Formal confirmation and financial details regarding the potential $20 billion divestiture of the DePuy Synthes orthopedics unit would serve as a major valuation catalyst.
- Continued commercial uptake and market penetration of newly approved therapies like ICOTYDE and expanded indications for the multiple myeloma portfolio will drive near-term revenue growth.
- Upcoming earnings calls and management updates on capital allocation strategy will be critical for assessing the company's ability to maintain its dividend growth and fund R&D.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceReportedJ&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next? · Published 2026-09-25 00:06:13Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedApollo’s Johnson & Johnson Deal Could Open a New Healthcare Growth Avenue - Yahoo Finance · Published 2026-09-25 00:06:13Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedApollo’s Johnson & Johnson Deal Could Open a New Healthcare Growth Avenue · Published 2026-09-25 00:06:13Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedNANOBIOTIX Provides First Half 2026 Operational and Financial Update · Published 2026-09-25 00:06:13Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedJ&J Gains 1.7% as Caplyta Opens a Mania Expansion Path · Published 2026-09-25 00:06:13Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.